Bio-AMD, Inc. is the 63% owner of Bio-AMD Ltd, a technology development company which is positioned in the fast growing Point of Care (PoC) medical diagnostics sector more.

The PoC market is growing fast. Forecasters suggest 10% growth per annum over the next 4-5 years will make the total market global worth over $22 billion.

Diagnostic testing accounts for only a low single digit % of healthcare expenditure worldwide, yet influences around two thirds of healthcare decisions. Driven by patient need and cost savings, hand-held devices offering rapid diagnostic testing are replacing slow and expensive laboratory analysis across a widening range of indications more.

Bio-AMD has targeted three initial PoC products for development, each using a similar technology platform to be applied into specific market segments more.